Compare Linde PLC (LIN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs ResMed Inc. — how do they compare? Linde PLC trades at $512 (market cap $236.74B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: Linde PLC is far larger — about 8.2× ResMed Inc.'s market cap, and Linde PLC pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| LIN | RMD | |
|---|---|---|
Market Cap | $236.74B | $28.81B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $293.73 |
52-Week Low | $389.38 | $182.82 |
Enterprise Value | $259.10B | $27.99B |
Dividend Yield | 1.25% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $512.05, down 0.2% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with revenue growth to $34.0B in 2025. Recent Q1 2026 results showed EPS of $4.33 beating estimates, while analyst consensus remains strongly bullish with 89% buy ratings and a $564.80 price target.
LIN presents a compelling long-term investment with premium valuation metrics offset by exceptional profitability and dividend growth. Key risks include elevated debt levels (debt-to-asset ratio rising to 31.63% in 2025) and potential margin pressure from economic cycles. The current technical weakness may offer entry points for investors seeking quality industrial exposure with sustainable growth prospects.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
